The Willi Stahlhofen Award is given to a high impact manuscript in the Journal of Aerosol Medicine and Pulmonary Drug Delivery and is presented at the ISAM Congress which was held in Aug 2023 in Saarbrucken Germany. The winner of the 2023 Willi Stahlhofen award was a manuscript with Lovelace Biomedical’s Scientist Conor Ruzycki as a co-author (https://www.liebertpub.com/doi/10.1089/jamp.2021.0002). This work … Read More
Inhalation delivery of nucleic acid gene therapies in preclinical drug development
Inhaled gene therapies hold great promise in treating a number of diseases including cystic fibrosis and certain cancers of the lung, but the development of these types of therapies is immensely challenging. Lovelace Biomedical has been and remains at the forefront in translational research for inhaled gene therapies. In this review article, Lovelace Biomedical aerosol scientists describe several of these … Read More
Lovelace Biomedical Wins 10M to Combat Opioid Overdose
Lovelace Biomedical has recently received 3 new grants and contracts worth over 10 million granted by the National Institutes of Health (NIH) to research and study treatments and cures against opiate-induced respiratory depression. We’re working with the NIH and other biomedical research laboratories to help develop and evaluate novel treatments to help mitigate this devastating public health problem. After the … Read More
Novel bioanalytical approaches to drug development – 5-AZA a case study to be presented at the 67th ASMS Conference in Atlanta
Within drug development, the quantitation of drug levels within the systemic circulation and target tissues can provide insight into tolerance and / or efficacy. For small molecules the mainstay for quantitative analysis is LC-MS/MS. 5-azacytidine has been used in the treatment of lung cancer, and for years the nucleosidic nature of 5-azacytidine resulted in significant interference with parent compound’s MRM … Read More
Promising Toxicokinetics for Treating Pulmonary Nontuberculous Mycobacteria Infection
Melanie Doyle-Eisele, Ph.D. and Director of Life Sciences, and Philip Kuehl, Ph.D, and Director of Scientific Core Laboratories, have recently partnered with various biomedical researchers to publish the results of the recent publication entitled: Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection. Pulmonary nontuberculous mycobacteria infection, or NTM, is an opportunistic pathogen that develops … Read More
Characterization of Dry Powder Inhaler Performance
Dr. Conor Ruzycki, an Aerosol Engineer here at Lovelace Biomedical, has recently published his article titled: Characterization of Dry Powder Inhaler Performance through Experimental Methods, where he discusses various platforms that dry powder inhalers (DPIs) are capable of delivering powder formulations of inhaled therapeutics. In his article, Dr. Conor Ruzycki outlines the focus of the developments in treating not only … Read More
Lovelace Biomedical will be Presenting Data on the Non-clinical and Clinical Development Work for HFA-152a at the Upcoming RDD Meeting
Lovelace Biomedical is excited to be presenting data on the non-clinical and clinical development work for HFA-152a at the upcoming RDD meeting: Register for the Meeting Scientists Philip Kuehl and Jacob McDonald will both be in attendance. If you have any interest in meeting with them reach out and make time to set up a meeting.
Hammad Irshad – Using a Degree in Engineering to Make a Difference in Public Health
Hammad has 18 years experience, and focuses on our aerosol development and delivery for novel therapies. Hammad, tell me what you do as an aerosol scientist at Lovelace. Overall, my work leverages Lovelace’s broad capabilities in aerosol science to answer important questions that improve public health and regulations. The work is exciting because we are able to work at the cutting edge … Read More
PCR Development, it’s Uses, and Important Research at Lovelace Biomedical, with Bryan Gullick, PhD, Bioanalytical Research Scientist
Staff Spotlight: Bryan Gullick, PhD, Research Scientist Bryan Gullick, PhD, Bioanalytical Research Scientist Bryan, tell us about PCR in the development and conduct of pharmacology and toxicology studies PCR assay development closely follows the in vivo studies required to support an IND. Along this path from pharmacology to toxicology the scientific team reviews, and evaluates what species to utilize. They will consider … Read More
Preclinical Drug Development for a Gene Therapy Product: No Cookie Cutter Route
Follow these critical steps on your path to IND application. By Philip J. Kuehl, PhD, Senior Scientist and Director of Scientific Core Laboratories, Lovelace Biomedical and Jacob D. McDonald , PhD, Senior Scientist and Chief Scientific Officer, Lovelace Biomedical Cell and gene therapy products are reviewed and approved through the Center for Biologics Evaluation and Research (CBER) at the Food and Drug Administration … Read More